0Z2 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Alector, Inc. (0Z2) stock, based on analyst opinions. It includes financial data such as past earnings, revenue, net income, and EBITDA, along with important dates like the next earnings report. The piece also answers frequently asked questions about the company's stock dynamics, employee count, and how to trade its shares.
Alector, Inc. Actuals & Estimates (NASDAQ:ALEC)
This article provides an overview of Alector, Inc. (NASDAQ:ALEC) stock performance, financial estimates, and analyst forecasts. It covers metrics such as current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The information is presented in a Q&A format, detailing various financial aspects and investment considerations for ALEC.
ALEC Forecast — Price Target — Prediction for 2027
This article provides a forecast, price target, and prediction for Alector, Inc. (ALEC) stock for 2027, based on analyst opinions and financial data. It covers current stock price, historical performance, earnings reports, market capitalization, and volatility, along with a disclaimer that the information is not investment advice.
Enterprise value to EBIT forward of Alector, Inc. – NASDAQ:ALEC
The article displays the enterprise value to EBIT forward for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data snippet from a larger platform, possibly TradingView, focusing solely on this specific financial metric for the given company.
Enterprise value to revenue forward of Alector, Inc. – NASDAQ:ALEC
This article briefly highlights the "Enterprise value to revenue forward" metric for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data point provided by TradingView, a financial markets platform. The content primarily focuses on the company's financial data and general market information.
Price to book forward of Alector, Inc. – GETTEX:0Z2
The article discusses the "Price to book forward" metric for Alector, Inc. (GETTEX:0Z2), available on TradingView under its financial data section. It highlights that this specific financial data point is "Made by humans" and is part of the comprehensive information available for the biotechnology company. The content primarily serves as a breadcrumb trail on the TradingView platform, guiding users through market data, financial figures, and other related services.
Alector (NASDAQ: ALEC) director receives new RSU and stock option awards
Alector (NASDAQ: ALEC) director Elizabeth A. Garofalo was granted new equity compensation on June 17, 2026. This included 28,700 restricted stock units (RSUs) vesting on June 17, 2027, or the date of the next annual stockholder meeting, and stock options for 9,450 shares vesting in 12 equal monthly installments starting July 17, 2026, and expiring on June 16, 2036. Following these awards, Garofalo directly holds 118,650 shares of Common Stock and 9,450 stock options in the company.
Alector Inc (ALEC) Financial Health: Profitability & Balance Sheet Analysis
Alector Inc (ALEC) currently has a weak financial status and low operating efficiency, ranking 312 out of 389 in the Biotechnology & Medical Research industry with a financial score of 5.88. The company reported a significant year-over-year decrease in revenue (71.53%) and net profit (43.34%) in its latest quarter. Key financial metrics such as cash and cash equivalents, total assets, total liabilities, and free cash flow have not been fully disclosed by the company.
Alector Inc (ALEC) Institutional Confidence
Alector Inc (ALEC) has an institutional shareholding score of 7.00, placing it 81st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 80.95%, showing a 17.91% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.16% of outstanding shares.
Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough
Alector's fair value remains steady at US$3.10 per share, despite mixed analyst sentiment regarding tau-targeting therapies in Alzheimer's. While some analysts view Biogen's CELIA data as validating the approach and Alector's potential, others caution that the CELIA trial missed its primary endpoint, highlighting challenges in translating biomarker wins into cognitive outcomes. The company's narrative continues to evolve with new data and funding decisions.
Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Alector Inc (ALEC), noting its current valuation score of 6.91 in the Biotechnology & Medical Research industry. It details the stock's current price, market cap, and P/E ratio, while indicating that P/B, P/S, and P/CF data have not yet been disclosed by the company. The article also highlights that the P/E ratio is significantly below its recent high and above its recent low.
Alector Inc (ALEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Alector Inc (ALEC), including its current price momentum score, support and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, offering buy, sell, or neutral signals. The analysis suggests ALEC is suitable for range-bound swing trading with a current overall signal indicating "Sell" based on moving averages and other technical indicators.
Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Alector Inc (ALEC), listing major shareholders and providing a breakdown of shareholder types, including investment advisors, hedge funds, and venture capital. It also presents institutional shareholding data over several quarters and recent shareholder activity with changes in holdings for key entities.
Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article concerns Alector Inc (ALEC) and its revenue breakdown by business segments, regional revenue, and profit contribution. However, the article states that relevant data for these categories have not been disclosed by the company yet. It primarily serves as a placeholder or an indication that this information is currently unavailable from Alector Inc.
Alector (ALEC) director receives 28,700 RSUs and 9,450-share option grant
Alector, Inc. director Richard H. Scheller received 28,700 restricted stock units (RSUs) and a stock option for 9,450 shares of common stock, as detailed in a recent Form 4 SEC filing. The RSUs vest on the earlier of June 17, 2027, or the company's next annual stockholder meeting, and the stock option vests in 12 equal monthly installments starting July 17, 2026, expiring on June 16, 2036. Following these grants, Scheller directly holds 134,899 shares of Alector common stock.
Alector Inc (ALEC) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Alector Inc (ALEC)'s dividend and stock split history, noting that the company has not distributed any dividends over the past five years and has no record of stock splits. It presents current stock performance data including its latest trading price, market capitalization, and daily change.
Alector (ALEC) board member receives new RSUs and long-dated stock options
Alector, Inc. director Paula Hammond received new equity awards comprising 28,700 restricted stock units (RSUs) and a stock option for 9,450 shares, as detailed in a recent Form 4 filing. The RSUs vest by June 17, 2027, or the next annual stockholder meeting, while the stock options vest monthly starting July 17, 2026. Following these transactions, Hammond directly holds 103,609 shares of Alector common stock.
[8-K] Alector, Inc. Reports Material Event
Alector, Inc. (ALEC) reported the results of its 2026 annual meeting of stockholders. Shareholders elected three Class II directors, ratified Ernst & Young LLP as their independent registered accounting firm for 2026, and approved the compensation of named executive officers on a non-binding advisory basis. The full 8-K filing details the voting results for each proposal.
Alector (ALEC) director awarded stock and options vesting through 2027
Alector, Inc. director Mark Altmeyer has been granted equity awards consisting of 28,700 restricted stock units (RSUs) and options for 9,450 shares of common stock. The RSUs vest by June 17, 2027, or the company's next annual stockholder meeting, while the stock options vest in 12 equal monthly installments starting July 17, 2026, or fully on the earlier of one year from grant or the next annual meeting. Following these transactions, Altmeyer directly holds 98,650 shares of common stock and 9,450 stock options.
Alector (NASDAQ: ALEC) director receives RSU and stock option grants
Alector director Louis J. Lavigne Jr. reported new equity compensation, including 28,700 restricted stock units (RSUs) and a stock option for 9,450 shares. The RSUs vest by June 17, 2027, or the next annual meeting, while the stock option vests in monthly installments starting July 17, 2026. Following these grants, Lavigne Jr. holds 128,109 direct common shares and 10,552 indirect common shares through Lavrite, LLC.
Alector (ALEC) director Kristine Yaffe granted 28,700 RSUs and options
Alector director Kristine Yaffe was granted 28,700 restricted stock units (RSUs) and options for 9,450 shares as part of her compensation. These equity awards are set to vest over time, with the RSUs vesting by June 17, 2027, or the next annual meeting, and the options vesting in monthly installments starting July 17, 2026. Following these grants, Yaffe directly holds 124,109 shares of Alector common stock, and the transaction is categorized as compensation-related rather than an open-market purchase or sale.
This Insider Has Just Sold Shares In Alector
Alector's Co-Founder, Arnon Rosenthal, recently sold US$172k worth of shares, which represents a small portion of his total holding. This follows an earlier, larger sale this year, both of which occurred at prices higher than the current stock price, mitigating some concerns about the selling. Despite these sales, insiders at Alector own 6.2% of the company, suggesting some alignment with shareholder interests, though no insider buying has been observed in the past year.
This Insider Has Just Sold Shares In Alector
Alector's Co-Founder, Arnon Rosenthal, recently sold US$172k worth of shares, representing 1.5% of his holding. This follows an earlier, larger sale of US$174k worth of shares. While the sales occurred at prices above the current market value, the lack of insider buying and relatively low insider ownership (6.2%) suggest caution for potential investors.
ALEC - Alector Inc Stock Price and Quote
This article provides a comprehensive overview of Alector Inc. (ALEC) stock, including its latest close price, financial metrics, analyst ratings, and a detailed list of recent news and insider transactions. Key financial data like market cap, income, sales, and various ratios are presented, alongside a history of analyst upgrades and downgrades, and significant company announcements related to clinical trials and financial results.
[Form 4] Alector, Inc. Insider Trading Activity
Alector, Inc. Director Richard H. Scheller reported an acquisition of 10,833 shares of Common Stock in the form of restricted stock units (RSUs) via a Form 4 filing. These RSUs will vest in four equal quarterly installments starting June 1, 2026. Following this grant, Scheller directly holds 106,199 shares.
[Form 4] Alector, Inc. Insider Trading Activity
Alector, Inc.'s Principal Accounting Officer, Grace Wong-Sarad, reported open-market sales of 9,184 shares of company common stock over two days to cover tax obligations related to vesting restricted stock units. The sales, made under a pre-arranged Rule 10b5-1 trading plan, totaled approximately $17,813, with Wong-Sarad retaining 95,461 shares post-transactions. This filing provides details on the transaction dates, prices, and the purpose of the sales.
Alector (ALEC) CEO sells shares to cover RSU tax obligations
Alector, Inc. CEO Arnon Rosenthal disposed of 87,216 shares of common stock on June 2, 2026, at a weighted average price of $1.9743 per share. This sale was conducted to cover tax obligations arising from the vesting of restricted stock units (RSUs). Post-transaction, Rosenthal holds 2,367,206 shares directly, with additional indirect holdings through family trusts.
Alector (ALEC) CFO Berkley sells shares to cover RSU tax obligations
Alector, Inc. CFO and Chief Business Officer Neil Lindsay Berkley sold 19,360 shares of common stock on June 2, 2026, at a weighted average price of $1.9742 per share. This sale was conducted to fulfill tax obligations arising from the vesting of restricted stock units (RSUs). Following the transaction, Berkley directly holds 379,900 shares of Alector common stock.
Alector (NASDAQ: ALEC) Rule 144 notice lists RSU vesting and stock sales
Alector, Inc. (NASDAQ: ALEC) has filed a Rule 144 notice detailing recent common stock activity, including the vesting of 10,295 Restricted Stock Units (RSUs) on June 1, 2026. The filing also reports multiple open-market stock dispositions by Grace Wong-Sarad between February and April 2026. These transactions involve common stock listed on Nasdaq and highlight insider activity related to RSU vesting and subsequent sales.
Alector (NASDAQ: ALEC) files to sell 132,805 RSU shares after vesting
Alector, Inc. (NASDAQ: ALEC) has filed a Form 144 to notify the proposed sale of 132,805 shares of common stock stemming from the vesting of restricted stock units on June 1, 2026. This filing also discloses previous sales of 81,864 shares on March 2, 2026, which generated proceeds of $173,825.38. These transactions are being handled through Morgan Stanley Smith Barney, with Nasdaq listed as the market.
Alector halts mid-stage trial for Alzheimer’s candidate developed with GSK
Alector has announced the discontinuation of its mid-stage clinical trial for the Alzheimer's disease drug AL002, which was being developed in collaboration with GSK. This decision was made due to an interim analysis showing that the drug did not meet the prespecified efficacy threshold, leading to the early termination of the Phase 2 study.
Number of shareholders of Alector, Inc. – DUS:0Z2
This article provides limited, primarily navigational content concerning Alector, Inc. (DUS:0Z2) on the TradingView platform. It shows the company's stock exchange listing and mentions sections like financials, news, and community discussions. However, the core information regarding the "Number of shareholders" is presented with empty values for "Period," "Value," and "Change," implying the data is either unavailable or has not been loaded.
Polaris entities hold 4.85M ALEC shares (ALEC) — Amendment No.7
Polaris entities and affiliated individuals have updated their beneficial ownership in Alector, Inc. (ALEC) through an Amendment No. 7 to Schedule 13G/A. As of April 30, 2026, Polaris-related funds and their managing members collectively report shared voting and dispositive power over 4,853,817 shares, representing a 4.4% stake based on Alector's 110,362,581 outstanding shares as of February 20, 2026. This amendment clarifies specific holdings across Polaris funds and details the shared control among key individuals.
Alector (NasdaqGS:ALEC) Stock Forecast & Analyst Predictions
Alector (ALEC) faces financial challenges with revenue expected to decline by 7.5% per annum and negative return on equity. Despite some positive EPS revisions, the company recently announced the discontinuation of a Phase 2 Alzheimer's disease trial and is focusing on its Blood-Brain Barrier technology platform. Analyst price targets have fluctuated, reflecting both renewed confidence in certain programs and ongoing concerns about volatility, insider selling, and unprofitability.
Alector Establishes $125 Million At-the-Market Offering
Alector, Inc. has entered into a sales agreement with TD Securities (USA) LLC to establish a $125 million at-the-market offering for common stock. This provides Alector with financial flexibility for general corporate purposes, including R&D and potential acquisitions. Despite the financing option, a recent analyst rating on ALEC stock is a Sell with a $2.00 price target, and TipRanks' AI Analyst shows a Neutral rating due to weak financial performance.
ALECTOR INC - MAY OFFER AND SELL COMMON STOCK UP TO $125 MLN THROUGH TD COWEN - SEC FILING
Alector Inc. (ALEC) has filed with the SEC to offer and sell up to $125 million of its common stock. The offering will be made through TD Cowen as its sales agent. This follows a previous filing in February for a similar at-the-market offering through Goldman Sachs.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its first-quarter 2026 financial results, highlighting $206.5 million in cash, cash equivalents, and investments, which are expected to fund operations through 2027. The biotechnology company provided updates on its Alector Brain Carrier (ABC) platform, which is advancing multiple therapeutic modalities for neurodegenerative diseases like Alzheimer's and Parkinson's. The company also noted a decrease in revenue and operating expenses compared to Q1 2025, resulting in a reduced net loss for the quarter.
Alector (ALEC) Reports Q1 Revenue Shortfall Amidst Strategic Dev
Alector Inc. (ALEC) reported a Q1 revenue of $1.05 million, significantly missing the anticipated $11.03 million, raising concerns among investors despite CEO Arnon Rosenthal's emphasis on strategic progress in its blood-brain barrier platform. The company's GF Score™ of 36/100 highlights weaknesses in financial strength and profitability, further compounded by $0.3 million in insider selling and a high price-to-sales ratio, suggesting potential overvaluation and challenges in translating research into revenue.
Alector (NASDAQ: ALEC) narrows Q1 2026 loss as it refocuses pipeline
Alector reported a narrower net loss in Q1 2026, reaching $22.9 million compared to $40.5 million a year prior, primarily due to significant reductions in operating expenses following 2025 workforce reductions and program wind-downs. Despite a decline in collaboration revenue from its GSK partnership, the company's cash reserves of $206.5 million are expected to fund operations through at least 2027. Alector is now repositioning its pipeline to focus on its ABC blood-brain barrier platform and preclinical programs, after GSK discontinued the Phase 2 PROGRESS-AD trial for nivisnebart in April 2026 due to a futility analysis.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its first-quarter 2026 financial results, highlighting $206.5 million in cash, cash equivalents, and investments, projected to fund operations through at least 2027. The company is advancing its Alector Brain Carrier (ABC) platform, with programs like AL037/AL137, AL050, and AL164 targeting Alzheimer’s and Parkinson’s diseases, while also announcing the discontinuation of its PROGRESS-AD Phase 2 trial for nivisnebart due to a futility analysis. Financials show decreased revenue and R&D expenses compared to Q1 2025, resulting in a net loss of $22.9 million for the quarter.
Alector Establishes $125 Million At-the-Market Offering
Alector has announced a $125 million at-the-market stock offering program with TD Securities (USA) LLC, allowing the company to sell common stock to fund general corporate purposes, including R&D, manufacturing, and potential strategic transactions. This arrangement provides financial flexibility without immediate shareholder dilution. Despite a recent "Sell" rating and a $2.00 price target from analysts, TipRanks’ AI Analyst, Spark, rates ALEC as Neutral, noting weak financial performance but strong technicals.
Alector Establishes $125 Million At-the-Market Offering
Alector, a biotechnology company, has entered into a sales agreement with TD Securities (USA) LLC to sell up to $125 million of common stock through at-the-market or negotiated offerings. These proceeds will fund research and development, manufacturing, working capital, and potential acquisitions. An analyst rating on ALEC stock is a Sell with a $2.00 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to weak financial performance despite technical strengths.
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) reported a Q1 loss of $0.21 per share, which was better than the Zacks Consensus Estimate of a $0.35 loss, representing an earnings surprise of +40.00%. However, the company missed revenue estimates, posting $1.05 million against an expected $3.01 million. Due to an unfavorable estimate revisions trend, Alector currently holds a Zacks Rank #4 (Sell), suggesting underperformance in the near future.
Alector (NASDAQ: ALEC) files $125M ATM offering with TD Cowen
Alector (NASDAQ: ALEC) has filed a $125 million "at-the-market" (ATM) common stock offering with TD Cowen. The proceeds are intended for general corporate purposes, including research, development, manufacturing, working capital, capital expenditures, and potential strategic transactions. This offering could dilute existing shareholders, with an assumed dilution of $1.74 per share for new investors based on a reference price of $2.57.
Alector (NASDAQ: ALEC) establishes $125M stock ATM facility
Alector, Inc. (NASDAQ: ALEC) has established a new At-The-Market (ATM) sales agreement with TD Securities (USA) LLC, allowing it to offer and sell up to $125 million of common stock. The company plans to use the net proceeds for general corporate purposes, including research, development, and potential acquisitions. Sales will occur on The Nasdaq Global Select Market, with TD Cowen receiving up to 3.0% of the gross sales price as compensation.
Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus
Alector (NASDAQ: ALEC) reported its Q1 2026 financial results, revealing a narrowed net loss of $22.9 million and a strategic pivot towards its Alector Brain Carrier (ABC) platform. This shift follows the discontinuation of its Phase 2 Alzheimer's trial for nivisnebart due to a futility analysis. The company maintains a cash runway expected to fund operations through at least 2027, focusing on advancing multiple preclinical ABC-enabled programs for neurodegenerative diseases.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its first-quarter 2026 financial results, highlighting a cash position of $206.5 million, sufficient to fund operations through 2027. The company is advancing its Alector Brain Carrier (ABC) platform, with programs like AL037/AL137 for Alzheimer's and AL050 for Parkinson's disease currently in preclinical development. Alector also announced the discontinuation of the PROGRESS-AD Phase 2 clinical trial for nivisnebart due to futility.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its first-quarter 2026 financial results, with cash, cash equivalents, and investments totaling $206.5 million as of March 31, 2026, projected to fund operations through 2027. The company highlighted advancements in its Alector Brain Carrier (ABC) platform, including programs for Alzheimer's and Parkinson's diseases, while also announcing the discontinuation of the PROGRESS-AD Phase 2 clinical trial for nivisnebart due to a futility analysis.
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Alector (ALEC)
This article summarizes recent analyst ratings for two healthcare companies: Establishment Labs Holdings (ESTA) and Alector (ALEC). TD Cowen reiterated a Buy rating for ESTA with a $95 price target, while Mizuho Securities maintained a Hold rating for ALEC with a $1.50 price target. The article also provides a consensus analyst rating and average price target for both companies.
Morgan Stanley raises Alector stock price target on pipeline focus By Investing.com
Morgan Stanley increased its price target for Alector Inc. (ALEC) to $2.00 from $0.90, maintaining an Underweight rating despite a recent trial failure. The firm views the AL101 trial setback as a "clearing event" that allows Alector to reallocate research and development funds to its promising ABC platform, which analysts believe can overcome previous delivery challenges. This follows a similar upgrade from BTIG, signaling renewed confidence in Alector's strategic shift toward blood-brain barrier therapeutics.
